Lexicon Pharmaceuticals Company Insiders
LXRX Stock | USD 0.77 0.04 4.94% |
Lexicon Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Lexicon Pharmaceuticals suggests that vertually all insiders are extremely bullish. Lexicon Pharmaceuticals employs about 285 people. The company is managed by 17 executives with a total tenure of roughly 17 years, averaging almost 1.0 years of service per executive, having 16.76 employees per reported executive.
Lonnel Coats CEO CEO and President and Director |
Lexicon Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2023-11-16 | Lonnel Coats | Acquired 90000 @ 1.05 | View | ||
2023-11-10 | Lonnel Coats | Acquired 10000 @ 1.01 | View | ||
2023-10-12 | Raymond Debbane | Acquired 148820 @ 1.03 | View | ||
2023-10-10 | Raymond Debbane | Acquired 508306 @ 1.14 | View | ||
2023-09-14 | Jeffrey L Wade | Acquired 10000 @ 1.38 | View | ||
2023-08-04 | Wendy Mcdermott | Acquired 6000 @ 1.84 | View | ||
2023-06-29 | Lonnel Coats | Acquired 10000 @ 2.16 | View | ||
2023-06-26 | Lonnel Coats | Acquired 10000 @ 2.18 | View | ||
2023-06-23 | Wendy Mcdermott | Acquired 10000 @ 2.43 | View | ||
2023-06-22 | Lonnel Coats | Acquired 40000 @ 2.31 | View | ||
2023-06-20 | Jeffrey L Wade | Acquired 12000 @ 2.33 | View | ||
2023-06-05 | International S.C.A. Artal | Acquired 27775050 @ 2.6 | View | ||
2022-08-01 | International S.C.A. Artal | Acquired 16173800 @ 2.5 | View |
Monitoring Lexicon Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Lexicon |
Lexicon Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4416) % which means that it has lost $0.4416 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3609) %, meaning that it created substantial loss on money invested by shareholders. Lexicon Pharmaceuticals' management efficiency ratios could be used to measure how well Lexicon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.91 in 2024. Return On Capital Employed is likely to rise to -0.82 in 2024. At this time, Lexicon Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 104.9 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 786.6 K in 2024.Common Stock Shares Outstanding is likely to rise to about 232.2 M in 2024, whereas Net Loss is likely to drop (123.1 M) in 2024.
Lexicon Pharmaceuticals Workforce Comparison
Lexicon Pharmaceuticals is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,188. Lexicon Pharmaceuticals retains roughly 285 in number of employees claiming about 13% of equities under Health Care industry.
Lexicon Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexicon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexicon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lexicon Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amouyal Philippe six days ago Acquisition by Amouyal Philippe of 8032 shares of Lexicon Pharmaceuticals subject to Rule 16b-3 | ||
Lisa DeFrancesco over a month ago Insider Trading | ||
Corrigan Brian over three months ago Insider Trading | ||
Artal International S.c.a. over six months ago Disposition of 1150922 shares by Artal International S.c.a. of Lexicon Pharmaceuticals subject to Rule 16b-3 | ||
Amouyal Philippe over six months ago Disposition of 8032 shares by Amouyal Philippe of Lexicon Pharmaceuticals subject to Rule 16b-3 | ||
Alan Main over six months ago Acquisition by Alan Main of 32903 shares of Lexicon Pharmaceuticals subject to Rule 16b-3 | ||
Kristen Alexander over six months ago Acquisition by Kristen Alexander of 15927 shares of Lexicon Pharmaceuticals subject to Rule 16b-3 | ||
Brian Crum over six months ago Disposition of 33457 shares by Brian Crum of Lexicon Pharmaceuticals subject to Rule 16b-3 |
Lexicon Pharmaceuticals Notable Stakeholders
A Lexicon Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lexicon Pharmaceuticals often face trade-offs trying to please all of them. Lexicon Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lexicon Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lonnel Coats | CEO and President and Director | Profile | |
Michael Exton | CEO Director | Profile | |
Jeffrey JD | President CFO | Profile | |
Alan Main | Executive VP of CMC and Supply Operations | Profile | |
Brian Crum | General VP | Profile | |
Kenneth MD | Senior Assurance | Profile | |
Chas Schultz | Executive Advocacy | Profile | |
Robert MD | Consultant Director | Profile | |
Tom Garner | Senior Officer | Profile | |
Desiree Gendron | Vice Training | Profile | |
Mike Kelly | Investor Officer | Profile | |
Thomas Garner | Senior Officer | Profile | |
Kristen Alexander | Vice Accounting | Profile | |
Dixon Terry | Vice Compliance | Profile | |
Carrie Siragusa | Vice Marketing | Profile | |
Wendy McDermott | Senior Resources | Profile | |
Lisa DeFrancesco | Corporate Relations | Profile |
About Lexicon Pharmaceuticals Management Performance
The success or failure of an entity such as Lexicon Pharmaceuticals often depends on how effective the management is. Lexicon Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lexicon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lexicon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.96) | (0.91) | |
Return On Capital Employed | (0.87) | (0.82) | |
Return On Assets | (0.77) | (0.73) | |
Return On Equity | (1.90) | (1.81) |
Please note, the imprecision that can be found in Lexicon Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lexicon Pharmaceuticals. Check Lexicon Pharmaceuticals' Beneish M Score to see the likelihood of Lexicon Pharmaceuticals' management manipulating its earnings.
Lexicon Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Lexicon Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lexicon Pharmaceuticals within its industry.Lexicon Pharmaceuticals Manpower Efficiency
Return on Lexicon Pharmaceuticals Manpower
Revenue Per Employee | 4.2K | |
Revenue Per Executive | 70.8K | |
Net Loss Per Employee | 621.5K | |
Net Loss Per Executive | 10.4M | |
Working Capital Per Employee | 508.8K | |
Working Capital Per Executive | 8.5M |
Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.